Mirtazapine Mylan

Mirtazapine, the active ingredient in Mirtazapine Mylan, is an antidepressant presented as an oral tablet for oral use. It works by modulating neurotransmitter activity and is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite. The medication is used under medical supervision to address depressive symptoms and associated functional impairment.

GNH USA supplies Mirtazapine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is an antidepressant that acts on serotonergic and noradrenergic pathways to treat depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Depressive episodes with prominent anxiety: alleviates both mood and anxiety components. Adjunctive therapy for treatment‑resistant depression: may enhance response when combined with other antidepressants.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Severe neutropenia or agranulocytosis - Elevated liver enzymes indicating hepatic injury - Suicidal thoughts or behavior, especially early in treatment

Before prescribing mirtazapine, clinicians should consider several safety aspects.

Assess psychiatric history: evaluate risk of suicidal ideation before initiating therapy. Monitor weight and metabolic parameters: watch for significant weight gain. Check liver function: consider baseline and periodic tests. Use caution in elderly: increased sensitivity to sedation and falls. Store at ambient temperature: keep in original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; a washout period is required. - CNS depressants (e.g., benzodiazepines, alcohol): may intensify sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce effectiveness. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for serotonin syndrome. - Anticholinergic drugs: additive dry mouth and constipation.